IP21-002, New Vaccine Surveillance Network
IP21-002,新疫苗监测网络
基本信息
- 批准号:10347837
- 负责人:
- 金额:$ 140.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
SUMMARY (For Components A, B, and C). Acute gastroenteritis (AGE) and acute respiratory illness (ARI)
are leading causes of childhood disease, accounting for a large proportion of hospitalizations, Emergency
Department (ED) visits, and outpatient visits annually in the US. These illnesses are caused by diverse
pathogens, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza viruses,
rhinovirus, enterovirus (EV), coronavirus including SARS-CoV-2, adenovirus, rotavirus, norovirus, astrovirus,
and sapovirus. Moreover, some of these viruses are associated with other emerging childhood syndromes,
including acute flaccid myelitis (AFM) associated with EV, and multisystem inflammatory syndrome in children
(MIS-C) associated with SARS-CoV-2. Thus, viral AGE and ARI are of major public health importance, and
result in serious long-term consequences for some children. There are few or no effective antivirals for these
viruses and vaccination is the most promising intervention. Our goals are to conduct active, prospective
population-based surveillance for AGE and ARI; to define the burden of vaccine-preventable diseases;
describe the clinical features, natural history, and population dynamics; and establish vaccine effectiveness
(VE) of licensed and impending vaccines and monitor VE over time. The New Vaccine Surveillance Network
(NVSN) will facilitate these goals. We propose four Specific Aims:
Aim 1: to conduct prospective active surveillance for AGE due to norovirus, rotavirus, and other
enteric viruses among children seeking healthcare in ED, inpatient, and outpatient settings.
(Component A, Mandatory Component 1; Optional Component B)
Aim 2: to conduct prospective active surveillance for ARI due to respiratory viruses in these settings.
(Component A, Mandatory Component 1; Optional Component B)
Aim 3: to conduct prospective active surveillance for AFM syndrome in these settings. (Component A,
Mandatory Component 2)
Aim 4: to conduct prospective active surveillance for MIS-C. (Optional Component C)
The Pittsburgh site has extensive experience with pediatric clinical research, including as a top enrolling NVSN
site in the current NVSN cycle. UPMC Children’s Hospital of Pittsburgh (CHP) has a catchment area of >5.5
million people and admits >95% of hospitalized children in the surrounding county of >1.2 million. Thus, the
environment is excellent for population-based research. The experienced investigative team includes experts
from pediatric infectious diseases, critical care, rheumatology, and cardiology. The data and samples collected
in this project will facilitate the capacity to calculate VE for multiple licensed and pending vaccines. The results
of this project will inform best practices for diagnosis and treatment, guide vaccine recommendations, and
determine public health interventions to prevent viral illness-related medical visits among children.
概述(A、B、C组件)急性胃肠炎(AGE)和急性呼吸道疾病(ARI)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marian G Michaels其他文献
Presentation, anagement, and outcomes of norovirus in adult and pediatric solid organ and hematopoietic stem cell transplant recipients: A multicenter, retrospective study.
诺如病毒在成人和儿童实体器官和造血干细胞移植受者中的表现、管理和结果:一项多中心回顾性研究。
- DOI:
10.1111/tid.14270 - 发表时间:
2024 - 期刊:
- 影响因子:2.6
- 作者:
Michelle Callegari;Lara A Danziger;Anne Rose;Daniel Kaul;Kelly Shaffer;Pearlie P Chong;D. Florescu;Kaci German;Robin Avery;M. Nguyen;Brett Wildfeuer;Marian G Michaels;Michael Green;Kexin Guo;Lihui Zhao;Amna Daud;Michael G. Ison - 通讯作者:
Michael G. Ison
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016–2020
5 岁以下儿童呼吸道合胞病毒病(按亚型)的季节性、临床特征和结果:新疫苗监测网络,美国,2016-2020 年
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:11.8
- 作者:
Ariana P Toepfer;Justin Z Amarin;A. Spieker;Laura S Stewart;M. Staat;E. Schlaudecker;Geoffrey A. Weinberg;Peter G. Szilagyi;Janet A Englund;Eileen J. Klein;Marian G Michaels;John V. Williams;R. Selvarangan;Christopher J. Harrison;Joana Y. Lively;P. A. Piedra;V. Avadhanula;B. Rha;James D. Chappell;M. McMorrow;Heidi L Moline;Natasha B. Halasa - 通讯作者:
Natasha B. Halasa
Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016-2022.
5 岁以下儿童呼吸道合胞病毒相关住院情况:2016-2022 年。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:8
- 作者:
M. McMorrow;Heidi L Moline;Ariana P Toepfer;Natasha B. Halasa;Jennifer E. Schuster;M. Staat;John V. Williams;Eileen J. Klein;Geoffrey A. Weinberg;Benjamin R. Clopper;J. Boom;Laura S Stewart;R. Selvarangan;E. Schlaudecker;Marian G Michaels;Janet A Englund;Christina S Albertin;Barbara E. Mahon;Aron J. Hall;Leila C. Sahni;A. Curns - 通讯作者:
A. Curns
Respiratory syncytial virus: a comparison of diagnostic modalities.
呼吸道合胞病毒:诊断方式的比较。
- DOI:
- 发表时间:
1992 - 期刊:
- 影响因子:0
- 作者:
Marian G Michaels;C. Serdy;K. Barbadora;Michael Green;A. M. Apalsch;Ellen R. Wald - 通讯作者:
Ellen R. Wald
Marian G Michaels的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marian G Michaels', 18)}}的其他基金
IP21-002, New Vaccine Surveillance Network
IP21-002,新疫苗监测网络
- 批准号:
10472400 - 财政年份:2021
- 资助金额:
$ 140.21万 - 项目类别:
IP21-002, New Vaccine Surveillance Network
IP21-002,新疫苗监测网络
- 批准号:
10674583 - 财政年份:2021
- 资助金额:
$ 140.21万 - 项目类别:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
狒狒 CMV——异种移植后的疾病风险
- 批准号:
2472249 - 财政年份:1997
- 资助金额:
$ 140.21万 - 项目类别:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
狒狒 CMV——异种移植后的疾病风险
- 批准号:
6169114 - 财政年份:1997
- 资助金额:
$ 140.21万 - 项目类别:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
狒狒 CMV——异种移植后的疾病风险
- 批准号:
2886043 - 财政年份:1997
- 资助金额:
$ 140.21万 - 项目类别:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
狒狒 CMV——异种移植后的疾病风险
- 批准号:
2671441 - 财政年份:1997
- 资助金额:
$ 140.21万 - 项目类别:
相似国自然基金
锌粉(002)晶面定向调控及其负极性能强化机理研究
- 批准号:2025JJ70625
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
新型核素偶联药载体JBN002-DOTA的开发及其在肿瘤诊疗中的应用
- 批准号:82373174
- 批准年份:2023
- 资助金额:60 万元
- 项目类别:面上项目
tiRNA-Val-CAC-002介导ITGB3/PI3K/Akt调控FB自噬促进OSF发生机制研究
- 批准号:2023JJ30946
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
双胍新衍生物SMK-002阻断PKM2入核下调脂质合成抑制EMT阻止膀胱癌转移的作用和机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
tiRNA-Gly-GCC-002 调控FKBP5 在狼疮性肾炎肾小管上皮细胞损伤中的作用及机制研究
- 批准号:LY22H050004
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
关键挥发性有机物介导根际促生菌NRCB002定殖的根际生物学机制
- 批准号:32172673
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
外泌体lncRNAuc002ktr.3在肺鳞癌顺铂耐药中的作用及其作为新型耐药标志物的临床价值
- 批准号:81972006
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
宿主LncRNAs LNC_002与Linc00152调控肠道病原菌感染炎症反应的分子机制研究
- 批准号:81902027
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
RELA/ LncRNA-uc002jit.1/PARP1形成环路调节DNA修复对DNA损伤药物清除白血病干细胞的影响
- 批准号:81872898
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
基因间长非编码RNA-UC002yug.2调控成骨细胞功能及其在绝经后骨质疏松症中的作用机制
- 批准号:81760595
- 批准年份:2017
- 资助金额:40.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Indication selection, patient stratification, and IND preparation for STX-002: the first-in-class LRG1 inhibitor for treatment of chronic kidney disease and immunotherapy-resistant tumours.
STX-002的适应症选择、患者分层和IND准备:用于治疗慢性肾病和免疫治疗耐药肿瘤的一流LRG1抑制剂。
- 批准号:
10092585 - 财政年份:2024
- 资助金额:
$ 140.21万 - 项目类别:
Collaborative R&D
RFA-DP-23-002, Improving Health Outcomes for Patients with Inflammatory Bowel Disease through Evidence-based Awareness, Referral, and Education Programs
RFA-DP-23-002,通过循证意识、转诊和教育计划改善炎症性肠病患者的健康结果
- 批准号:
10762917 - 财政年份:2023
- 资助金额:
$ 140.21万 - 项目类别:
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 140.21万 - 项目类别:
RFA-IP23-002 Adult Immunization Quality Improvement for Providers (IQIP)
RFA-IP23-002 提供者成人免疫质量改进 (IQIP)
- 批准号:
10764599 - 财政年份:2023
- 资助金额:
$ 140.21万 - 项目类别:
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education
RFA-DP-23-002,通过流行病学、加强疾病管理、传播和教育改善炎症性肠病患者的治疗结果并减少差异
- 批准号:
10762688 - 财政年份:2023
- 资助金额:
$ 140.21万 - 项目类别:
CE23-002 - Assessing the Impact of Overdose Prevention Centers as a Polysubstance Use and Behavioral Health Intervention in New York City
CE23-002 - 评估纽约市过量预防中心作为多物质使用和行为健康干预措施的影响
- 批准号:
10783253 - 财政年份:2023
- 资助金额:
$ 140.21万 - 项目类别: